Approved in the United States and the European Union Safety-Related Regulatory Actions for Biologicals

[1]  Saurabh Aggarwal,et al.  What's fueling the biotech engine? , 2007, Nature Biotechnology.

[2]  R. Frank.  Regulation of follow-on biologics. , 2007, The New England journal of medicine.

[3]  S. Schneeweiss,et al.  Developments in Post‐marketing Comparative Effectiveness Research , 2007, Clinical pharmacology and therapeutics.

[4]  D. Furst,et al.  Combining enzyme specificity and tissue selectivity of cyclooxygenase inhibitors: towards better tolerability? , 2007, Rheumatology.

[5]  Gopi Shankar,et al.  A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs , 2007, Nature Biotechnology.

[6]  K. Winthrop,et al.  Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor , 2006, Nature Clinical Practice Rheumatology.

[7]  A. Aksamit.  Review of Progressive Multifocal Leukoencephalopathy and Natalizumab , 2006, The neurologist.

[8]  Nicki Panoskaltsis,et al.  Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. , 2006, The New England journal of medicine.

[9]  Gary Walsh,et al.  Biopharmaceutical benchmarks 2006 , 2006, Nature Biotechnology.

[10]  W. Jiskoot,et al.  Eprex-associated pure red cell aplasia and leachates , 2006, Nature Biotechnology.

[11]  I. Buchan,et al.  Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. , 2006, JAMA.

[12]  P. Kurki,et al.  Differences in product information of biopharmaceuticals in the EU and the USA: implications for product development. , 2005, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[13]  H. Schellekens,et al.  Antibodies against Erythropoietin and Other Protein‐Based Therapeutics: An Overview , 2005, Annals of the New York Academy of Sciences.

[14]  H. Schellekens.  Follow-on biologics: challenges of the "next generation". , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[15]  C. Botsios.  Safety of tumour necrosis factor and interleukin-1 blocking agents in rheumatic diseases. , 2005, Autoimmunity reviews.

[16]  Bruce M Psaty,et al.  Detection, verification, and quantification of adverse drug reactions , 2004, BMJ : British Medical Journal.

[17]  C. Hamilton.  Infectious complications of treatment with biologic agents , 2004, Current opinion in rheumatology.

[18]  Christine Robinson,et al.  Preclinical safety testing of biotechnology-derived pharmaceuticals , 2004, Molecular biotechnology.

[19]  H. Schellekens.  The immunogenicity of biopharmaceuticals , 2003, Neurology.

[20]  W. Hennink,et al.  Shifting paradigms: biopharmaceuticals versus low molecular weight drugs. , 2003, International journal of pharmaceutics.

[21]  S. Wolfe,et al.  Timing of new black box warnings and withdrawals for prescription medications. , 2002, JAMA.

[22]  R. Temple,et al.  Safety of newly approved drugs: implications for prescribing. , 2002, JAMA.

[23]  J. Sims.  Assessment of biotechnology products for therapeutic use. , 2001, Toxicology letters.

[24]  R. Meyboom,et al.  Characteristics of Topics in Pharmacovigilance in The Netherlands , 1996 .

[25]  L. Lasagna,et al.  Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: A regulatory perspective , 1995, Clinical pharmacology and therapeutics.

[26]  P Gastmeier,et al.  Hospital-acquired infections related to contaminated substances. , 2007, The Journal of hospital infection.

[27]  A. Baumann.  Early development of therapeutic biologics--pharmacokinetics. , 2006, Current drug metabolism.

[28]  Hani Mickail,et al.  Pharmacovigilance during the Pre-Approval Phases , 2006, Drug safety.

[29]  Gary Walsh,et al.  Biopharmaceutical benchmarks , 2000, Nature Biotechnology.